Amedisys (AMED) Upgraded to Strong-Buy by BidaskClub

Amedisys (NASDAQ:AMED) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

Several other analysts have also weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Amedisys to $115.00 and gave the company an “outperform” rating in a research report on Friday, August 3rd. Robert W. Baird lifted their target price on shares of Amedisys from $105.00 to $120.00 and gave the company a “neutral” rating in a research report on Thursday, October 11th. Bank of America set a $139.00 target price on shares of Amedisys and gave the company a “buy” rating in a research report on Tuesday, September 18th. Cantor Fitzgerald initiated coverage on shares of Amedisys in a research report on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price on the stock. Finally, Canaccord Genuity initiated coverage on shares of Amedisys in a research report on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price on the stock. Five analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $105.50.

NASDAQ AMED opened at $120.50 on Thursday. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of 35.81, a P/E/G ratio of 1.76 and a beta of 1.22. Amedisys has a 52-week low of $49.80 and a 52-week high of $127.38.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Monday, October 29th. The health services provider reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.18. The company had revenue of $417.34 million for the quarter, compared to analyst estimates of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The business’s quarterly revenue was up 11.7% on a year-over-year basis. During the same period last year, the business posted $0.56 EPS. Research analysts forecast that Amedisys will post 3.58 EPS for the current fiscal year.

In other Amedisys news, insider David L. Kemmerly sold 3,375 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $117.44, for a total value of $396,360.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David B. Pearce sold 398 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total transaction of $48,440.58. Following the completion of the transaction, the insider now owns 11,818 shares in the company, valued at $1,438,368.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,273 shares of company stock worth $1,217,456. 2.60% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in AMED. Itau Unibanco Holding S.A. acquired a new position in Amedisys in the second quarter valued at about $149,000. Moneta Group Investment Advisors LLC acquired a new position in Amedisys in the second quarter valued at about $181,000. Cubist Systematic Strategies LLC boosted its position in Amedisys by 1,086.0% in the second quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after buying an additional 2,172 shares in the last quarter. Dorsey & Whitney Trust CO LLC acquired a new position in Amedisys in the third quarter valued at about $203,000. Finally, Quantitative Systematic Strategies LLC acquired a new position in Amedisys in the second quarter valued at about $217,000. Hedge funds and other institutional investors own 93.58% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

See Also: Does the discount rate affect the economy?

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply